Leidos Holdings, Inc. (NYSE: LDOS) — The Group’s Highest-Return Prime at Its Cheapest-Ever Multiple, Priced as if the Crown Jewel Is Already Lost

Report date: 2026-07-17 · Price: $106.48 (2026-07-17 close) · Shares: ~126–129M dil. · Market cap: ~$13.7B · Enterprise value: ~$19.5B · Fiscal year-end: Friday nearest Dec 31 (FY2025 ended 2026-01-02; Q1-FY2026 reported 2026-05-05) · Sector: Industrials · Government IT Services & Defense

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information, not investment advice. The analysis that follows carries no recommendation and no price target, by design; this section is the single exception.

Verdict: HOLD, leaning constructive — accumulate-on-weakness here and toward the ~$100 low; not a short. Framing: a deep-value, low-beta falling knife on a genuinely higher-quality-than-peers business, where a ~46% de-rating has priced a company-wide impairment for what the evidence says is a single-segment recompete risk. Fair-value zone ~$130–160 (~11–13x normalized EPS of ~$12); you are paid ~12% FCF yield to wait through the catalyst.

Leidos is the scale leader (~$17B revenue) of the cleared-government-services oligopoly and, unusually for the group, a business that actually earns its cost of capital and then some: ~14–16% ROIC, a genuine ~600bp spread over WACC — materially better than closest peer CACI’s ~10% cost-of-capital returns. That premium is not evenly spread. Leidos is a bimodal company: a 44%-of-revenue National Security flagship of undifferentiated ~10%-margin cleared labor, bolted to a 30%-of-revenue Health & Civil segment that throws off ~57% of operating income at a 23.7% margin — the QTC/VA disability-exam franchise, plus the FAA air-traffic incumbency and a rising defense-tech product core. The whole moat, and the whole return premium, lives in that concentrated high-margin book. That is precisely why the stock fell 46% from its ~$198 November-2025 all-time high to a $100 June-2026 low: the market decided the crown jewel is cracking. A fourth vendor has entered the VA-exam market, a recompete RFP is expected mid-2026, and Health & Civil backlog already slipped to $10.4B from $12.2B — so the Street re-priced the entire company as a no-growth annuity (P/E 9.75x, its cheapest ever — 1.7th percentile of its own decade; ~8x EV/EBITDA; ~1% implied perpetual growth on a reverse-DCF).

The reason I lean constructive rather than neutral is the gap between that pricing and the evidence. This is unambiguously cheap on every lens — the debate is “cheap-and-mispriced” vs. “cheap-and-broken,” not cheap-vs-expensive — and the disconfirming facts favor mispricing: management raised FY2026 guidance at the Q1 print (EPS $12.10–12.50), Q1 exam volumes “remained high,” TTM book-to-bill is 1.1x, IC/digital budgets are growing 4–5%/yr, and every published sell-side target ($115–160, even the bears) sits above spot while the stock keeps grinding lower on no fresh news. That configuration — targets above, price below, one unresolved binary — is the fingerprint of a defensive name the market can’t bring itself to own until the Health overhang clears. Against that, the bear owns two real facts: FY25’s 12.2% operating margin sits at a mix/incentive-fee-flattered peak, and if the recompete cuts scope or price on a 23.7%-margin book, normalized EPS is nearer ~$10 than ~$12 and the cheap multiple is deserved. I split the difference: own it for the ~12% FCF yield and ~$1.1B/yr of buybacks-plus-dividends at trough, size it as a value position not a table-pound, and respect that the knife has no momentum catalyst before the VBA RFP resolves. My fair-value zone is ~$130–160 (11–13x a ~$12 normalized number, ~9–10x EV/EBITDA — still a discount to CACI’s 16x); risk/reward turns genuinely compelling on any retest of the ~$100 low.

Conviction: medium. The single fact that flips me more bullish: the mid-2026 VBA disability-exam recompete resolving with LDOS’s share and ~20%+ Health margin intact (proof the reset is a one-year trim, not a franchise break) → re-rate toward 13–15x. The single fact that flips me bearish: a lost or scope/price-cut recompete, or Health segment margin breaking below ~18% in FY26 prints (proof the crown jewel is structurally impaired) — at which point ~$10 normalized EPS at a stuck 9–10x justifies the current price and lower. Tag: the highest-quality house on the government-shutdown street, marked down as if the roof already caved in — on one room.

📈 Stock Price Action — Five-Year Event Map

Factual price history and the events that most plausibly drove each move. Price moves are Fact; attributed causes are Interpretation. No recommendation, no price target, no chart-pattern reading.

The arc. Over five years LDOS round-tripped and then some: from ~$100 (mid-2021) down to a ~$74 trough (May 2023), then a ~2.7x melt-up to an all-time high of ~$197.91 on 2025-11-04, followed by a violent ~46% collapse to a $100.00 low on 2026-06-25 and a modest bounce to $106.48 (2026-07-17). The stock now sits ~46% below its November-2025 peak, near the bottom of a very wide 52-week range ($100–$198), and — critically — at the 1.7th percentile of its own ten-year P/E range (9.75x, cheapest ever). This is a low-beta (~0.45) defensive compounder that just suffered a franchise-questioning, not-yet-franchise-broken, de-rating.

Cycle narrative. (1) 2021–23 was a slow bleed: the market punished margin misses and weakness in the airport/port security-detection book, and rising rates compressed defensive-services multiples, bottoming near $74 in May 2023. (2) The 2023–24 melt-up was the NorthStar 2030 margin story made visible — operating margin climbed from ~8% toward 11%, the high-margin Health/QTC franchise scaled, and the November-2024 election added a defense-spend bid, carrying the stock to ~$187. (3) The winter-2025 drawdown was the DOGE shock — the market dumped every government contractor on fears of mass federal spending cuts, without distinguishing LDOS’s defense/health mix from Booz Allen’s civil-consulting exposure. (4) LDOS then re-rated to its ~$198 all-time high as it became clear the cuts largely missed it; the Q3-FY25 print on 2025-11-04 beat and management raised guidance, marking the exact peak. (5) From that peak the stock lost a third of its value into May 2026 as generic appropriations/continuing-resolution uncertainty combined with a FY2026 guide (delivered at the 2026-05-05 Q1 call) that the market read as decelerating. (6) The final leg to the $100 low was LDOS-specific: a cluster of sell-side downgrades in June 2026 (BofA to Neutral 6/17; a “no longer bullish — rising pressure across the Health portfolio” note the same day) crystallized fears that the crown-jewel VA disability-exam business faces volume normalization and recompete risk, layered on a Middle-East de-escalation that trimmed the whole defense complex’s risk premium. The move is a fact; whether it correctly prices a genuine Health-earnings impairment or an over-extrapolated air-pocket is the debate the body takes up.

1. Executive Summary

Leidos Holdings is the largest company in U.S. government services by revenue — ~$17.2B in FY2025, ahead of GDIT, Booz Allen, CACI, SAIC and Parsons — and, on the numbers, the highest-returning of the cleared-services primes. It sells labor and, increasingly, products into federal missions: intelligence and defense IT, cyber and mission software (the largest book), veterans’ medical-disability exams and air-traffic-control automation (the highest-margin book), homeland/energy-infrastructure engineering, and a rising defense-technology product line (passive radar, air defense, maritime autonomy). Roughly 87% of revenue is U.S. government, the balance international and commercial. It is asset-light (capex ~0.7% of revenue), converts revenue into cash unusually well (FY2025 FCF ~$1.6B, CFO/net-income ~1.2x), and earns a genuine ~14–16% ROIC — a ~7-point spread over its ~8–9% cost of capital that is real, not an artifact, and materially better than closest peer CACI’s cost-of-capital-hugging ~10%.

The defining structural fact is that Leidos is bimodal: its 30%-of-revenue Health & Civil segment throws off roughly 57% of segment operating income at a 23.7% margin (the QTC/VA disability-exam franchise, the FAA air-traffic incumbency), while the 44%-of-revenue National Security & Digital flagship is undifferentiated cost-plus and time-and-materials cleared labor earning only ~10%. The entire moat, and the entire return premium, is concentrated in a minority of the revenue — and, within that, disproportionately in a single, re-compete-exposed relationship with the Department of Veterans Affairs. That concentration is the whole investment debate.

It is also why the stock is where it is. Leidos tripled from a ~$74 mid-2023 low to a ~$197.91 all-time high on 2025-11-04 as CEO Tom Bell’s NorthStar 2030 program roughly doubled operating margin (7.7% in 2019 to 12.2% in FY2025) and the market extrapolated the expansion. It then fell ~46% to a $100 low by June 2026, a decline driven far less by results than by fear: a fourth vendor has entered the VA disability-exam market, a re-compete RFP is expected mid-2026, Health & Civil backlog slipped to ~$10.4B from ~$12.2B, and the whole government-services complex de-rated on DOGE/appropriations/continuing-resolution anxiety. The result is a valuation at genuine capitulation: P/E 9.75x — the 1.7th percentile of its own ten-year range, its cheapest multiple ever — ~8x EV/EBITDA and an ~11–12% free-cash-flow yield on the highest-margin book in the group. A reverse-DCF implies the price embeds only ~1% perpetual growth.

The tension is sharp and largely binary. The bear owns two real facts: FY2025’s 12.2% operating margin sits at a mix- and incentive-fee-flattered peak, and if the VA re-compete cuts scope or price on a 23.7%-margin book, normalized EPS is nearer ~$10 than the ~$12.30 the company guides — in which case a stuck 9–10x multiple is deserved, and the negative tangible book (goodwill $6.3B against equity $5.0B, an artifact of a roll-up with an impairment precedent) offers no cushion. The bull owns the disconfirming evidence: management raised FY2026 guidance at the Q1 print (non-GAAP EPS $12.10–12.50), Q1 exam volumes “remained high,” TTM book-to-bill is 1.1x, intelligence/digital budgets are growing 4–5%/yr, the balance sheet is investment-grade and self-deleveraging, and ~$1.1B/yr flows back to holders in buybacks and dividends. Tellingly, every published sell-side target ($115–160, even the bears) sits above spot, yet the stock keeps grinding lower — the fingerprint of a name the Street believes is cheap but won’t own until the Health overhang clears.

Two honest complications temper the bull. Capital allocation is adequate, not distinguished: the FY2023 ~$687M SES detection-business impairment is hard evidence of overpayment, much of the FY2024–25 buyback was executed near the cyclical price peak, and the new $2.4B, 73%-goodwill Entrust (grid-modernization engineering) deal — debt-funded, lifting net leverage to ~2.7x — carries the same profile it must now prove it has escaped. And no insider bought the crash — a single 2,000-share director purchase in twenty months, zero from the CEO or CFO — a mildly negative tell that management is not signaling a gift. This memo lays out both sides in full. It offers no recommendation and no price target outside Claude’s Take above; the debate it adjudicates is not cheap versus expensive — Leidos is unambiguously cheap on every lens — but cheap-and-mispriced versus cheap-and-broken, a fork that resolves almost entirely on the durability of one health-services franchise.

2. Business Overview

What Leidos is. Leidos Holdings is the largest U.S. government-services / defense-technology contractor by revenue — FY2025 revenue $17,174M (F, 10-K MD&A), ahead of GDIT (a ~$13B General Dynamics segment), Booz Allen (~$11.2B), CACI (~$8.6B), SAIC (~$7.5B) and Parsons (~$6.4B). Founded 1969 by physicist Robert Beyster (the original SAIC), the current company was created by the 2013 SAIC split and vaulted to scale with the 2016 reverse-Morris-trust acquisition of Lockheed Martin’s Information Systems & Global Solutions (IS&GS) business (~$5B of revenue). Headquartered in Reston, Virginia, it employs ~47,000 people (41,900 U.S.), of whom 53% hold U.S. security clearances and 19% are military veterans (F, 10-K Human Capital). It generated 87% of FY2025 revenue from U.S.-government contracts (prime or sub) and ~8% from outside the U.S. (F).

How it makes money. Leidos sells labor and, increasingly, products into federal missions: it staffs and runs IT, intelligence, health and engineering programs (the services core), and it designs/builds a growing layer of differentiated hardware and software — passive-radar and air-defense sensors, maritime autonomy, hypersonic structures, security-detection scanners, and mission/health software. It is overwhelmingly a prime contractor. Revenue is contractual and visible but re-compete-exposed: the bulk flows through multi-award IDIQ vehicles and GSA schedules as task orders that are periodically re-bid, so the “recurring” quality is an incumbency annuity, not a subscription — each vehicle must be re-won, and a lost re-compete can transfer both the work and the cleared people (F/I).

Segment structure — note the reorganization. The FY2025 10-K reports four reportable segments effective 2026-01-02 (F, 10-K “Our Business Segments”):

The single most important structural fact: Health & Civil is only 30% of revenue but ~57% of segment operating income, at a 23.7% margin — roughly 2.4x the corporate average and far above the low-double-digit / high-single-digit margins of the other three segments (F). Leidos’s profit engine is a minority of its revenue. (I) This is the crux of the entire investment debate and the reason the stock de-rated ~46% in 2026 on Health-margin fears.

• National Security & Digital (44%, 10.0% margin) — the biggest, lowest-margin book: digital modernization/IT, mission software, multi-domain, cyber operations, and IC intelligence-analysis/logistics. This is largely cost-plus and T&M staff-augmentation labor dressed in a technology label — the commoditized end of GovCon.
• Health & Civil (30%, 23.7% margin) — the crown jewel. Contains QTC / Leidos-QTC managed-health services (medical-disability and behavioral-health examinations for the VA/VBA via a national clinic footprint), the FAA air-traffic-control automation franchise (ERAM and successor programs), the DHMSM/MHS Genesis DoD+VA electronic-health-record program, plus energy/environment (DoE) and life-sciences (NIH). Management guides Health to “robust profitability above 20%” beyond 2026 (Q4-FY25 call).
• Commercial & International (13%, 7.2%) — energy-infrastructure engineering for utilities, security-detection products (airport/port/border scanners — >30,000 deployed in 120+ countries), and UK/Australia defense services.
• Defense Systems (13%, 7.2%, rising) — the defense-tech product arm (Dynetics/Gibbs & Cox heritage): maritime autonomy (MUSV/Seahawk), aerospace (space EO/IR, hypersonic structures), land systems (IFPC air-defense, ALPS passive radar), airborne ISR. Margins jumped 680bps in Q4-FY25 as programs entered production.

Segment re-cut for FY2026 (watch this). Effective Q1-FY2026, management realigned into five sectors rolling up to four new-name reporting segments: Intelligence & Digital, Health, Homeland, and Defense (F, Q4-FY25 & Q1-FY26 calls). “Homeland” now aggregates the old Commercial & International plus homeland-security work and the FAA air-traffic book pulled out of Health & Civil; “Health” becomes the purer managed-health book; “Defense” absorbs force-protection/logistics from the old National Security sector. This makes multi-year segment comparisons non-continuous and, notably, moves the lower-margin FAA/transportation revenue out of the reported “Health” line — which will optically raise the Health segment margin going forward (I; a disclosure discontinuity worth flagging to the reader).

Contract-type mix (FY2025): Cost-reimbursement + fixed-price-incentive 44%, Firm-fixed-price (FFP) 43%, T&M + fixed-price-level-of-effort 13% (F, 10-K). The by-segment split is analytically revealing: National Security & Digital is ~72% cost-plus/T&M (classic labor pass-through, capped fee, low operating leverage), whereas Health & Civil is ~60% FFP — the fixed-unit-rate QTC exam model, where Leidos keeps the savings from doing exams faster/cheaper. The margin premium and the moat both live in the fixed-price health book; the scale lives in the cost-plus labor book. (I)

Customer mix (FY2025): ~87% U.S. government; DoW + Intelligence Community together ~49% of revenue (F); the balance is DHS, FAA, VA/VBA, DoE, HHS/NIH, and international (UK MoD, Australian DoD, NATO) plus commercial utilities. Vs. CACI’s ~75% DoD concentration, Leidos is materially more diversified across civil/health/transportation — a double-edged trait (more insulated from any single defense-budget swing, but more exposed to the “efficiency/consulting” purge and to the single VBA health customer). (I)

Verdict (Business Overview): Leidos is the scale leader of the cleared-GovCon oligopoly — a diversified, prime-contractor, asset-light services business (~1% of revenue capex) with genuine visibility ($49B backlog) but a profit structure that is dangerously concentrated: a 30%-of-revenue Health & Civil segment throws off the majority of operating income at a 23.7% margin, while the 44%-of-revenue flagship is low-margin cost-plus labor. The business quality is bimodal — a high-return health/product core bolted onto a commodity-labor base. Understanding the durability of that Health book is the whole game.

3. Industry Dynamics

Structure — a fragmented oligopoly of cleared primes. Federal technology/mission services is a large, appropriations-backed demand pool served by a handful of scaled primes — Leidos (~$17.2B), GDIT (~$13B seg), Booz Allen (~$11.2B), CACI (~$8.6B), SAIC (~$7.5B), Parsons (~$6.4B), V2X (~$4.3B), Peraton, Amentum, SAIC — plus thousands of small-business set-aside firms and, at the high end, the defense OEMs (Lockheed, Northrop, RTX, L3Harris, GD) and consultancies (Accenture Federal, Deloitte, Optum in health). Leidos’s own 10-K names ~20 principal competitors spanning all of these (F). Work is competed as task orders under multi-award IDIQ/GWAC vehicles; award turns on past-performance scoring, technical rating and price. The market is structurally consolidated at the prime tier but competitively bid at the task-order level — high demand stability coexisting with persistent price pressure at the commoditized-labor end. (I)

Barriers to entry — real against newcomers, low among incumbents. The genuine moat of the industry is the entry barrier: security clearances and facility accreditations (years to obtain; 53% of Leidos staff cleared), DCAA-compliant cost-accounting systems, and a qualifying past-performance record. These cannot be offshored to low-cost labor and cannot be stood up quickly — protecting the incumbent primes as a class. But they do little to protect any one prime from the others: Leidos, CACI, SAIC and GDIT all clear their people and hold the same vehicles, so re-competes among them are genuine price/past-performance shootouts. (I) In Greenwald’s taxonomy this is an industry with modest, shared barriers to entry, not a set of individually defensible franchises.

Budget and appropriations dynamics — the swing variable. FY2025 ran under a full-year continuing resolution (the first full-year CR for DoD) but at higher topline — defense raised to ~$893B, with the OBBBA reconciliation act adding further defense/border funding — and Leidos flags IC budgets growing 4–5%/yr since 2022 with heavy classified spend on digital infrastructure (F/I, Q1-FY26 call). Against this favorable dollar backdrop sits chronic procurement friction: a six-week government shutdown in Q4-FY2025 cut Leidos’s Q4 revenue growth by ~7 points (~2 points for the full year), and management called out that “procurement is still recovering from the protracted government shutdown” into Q1-FY2026 (F). CRs and shutdowns delay new-start awards regardless of budget priority — the reason FY2025 net bookings fell to $17.5B (~1.0x book-to-bill) from $23.2B (~1.4x) in FY2024 and Q1-FY26 book-to-bill was only 0.8x (1.1x TTM). (F)

DOGE / “consulting-is-waste” efficiency purge — a differentiated hit. The 2025–26 federal-efficiency drive (DOGE) and advisory-spend crackdown bifurcated GovCon: civil-consulting-heavy Booz Allen took >$200M of terminations, cut ~7% of staff and guided its civil book down double digits, while defense/intel-weighted contractors rode the budget rotation. Leidos sits in between. It is less advisory-exposed than BAH (its civil work is mission delivery — health exams, air-traffic systems, EHR — not McKinsey-style consulting), and its defense/IC half (~49%) is on the favored side; but at 87% government and with a large civil/health book it is more exposed than ~75%-DoD CACI. The empirical read so far is resilient: FY2025 revenue +3.1% (~4% ex-shutdown/extra-week) with all four segments growing, and management repeatedly frames itself as aligned to administration priorities (border, homeland, defense-tech, AI). (F/I) The residual risk is not advisory cuts but efficiency pressure on the high-margin QTC health book (see /) and continued award-timing air-pockets.

FAR reform / AI. The 10-K flags “ongoing significant reform of the Federal Acquisition Regulation” enabling expanded competition from traditional and non-traditional entrants (Anduril, Palantir, Shield AI, SpaceX-adjacents) (F). Management’s stance is that AI is “an accelerant, not a threat” — compressing the low-value “easy to do” bottom of the value chain while their cleared access, regulatory permissions and proprietary data remain “hard to get” (Q1-FY26 call). That is a coherent argument, but it is management’s hypothesis, and AI’s deflation of the still-large cost-plus/T&M labor base (57%+ of revenue) is a genuine open question (I).

Marathon capital-cycle read. Two opposing currents. (1) On the demand side, elevated defense/IC/space/border budgets are drawing capital and new entrants into defense-tech (VC-funded munitions, autonomy, sensing, space) — a caution flag for acquisition prices (Leidos and CACI are both bidding into hot niches) and for eventual over-supply of “defense-tech” capacity that mean-reverts. (2) On the capital-discipline side, the traditional services primes are relatively asset-light and are shrinking share counts (Leidos retired 4.4% of shares in FY2025) rather than over-building — the healthier side of the cycle. The government customer is a monopsony that can insource, terminate for convenience and reprioritize at will, which caps the returns the industry can durably earn and periodically distorts the normal capital cycle (regulation/appropriations override supply-demand). (I)

Verdict (Industry): A moderately attractive industry, tilting favorable at present. Large, stable, appropriations-backed demand; high entry barriers (clearances, past-performance) that shield the incumbent primes from newcomers; and a budget mix rotating toward Leidos’s strengths. But it is structurally capped: a single monopsony customer with insourcing/termination power, commodity-labor price competition among clearance-equipped peers, chronic CR/shutdown award-timing risk, and a rising AI/FAR-reform threat to the labor model. It is a good place to be a scaled incumbent, not a place where anyone earns software-like economics on the base business — the excess returns come from the specific high-barrier franchises (health, FAA, product IP), not from the industry itself.

4. Competitive Position

The moat, named. Leidos’s advantage is a narrow, bimodal moat: (1) a broad but shallow incumbency + clearances + past-performance advantage across the whole book (Greenwald customer-captivity / intangibles, reinforced by modest scale economies as the #1 prime), plus (2) a deep, genuinely durable franchise moat concentrated in three pockets — the QTC managed-health business, the FAA air-traffic-automation incumbency, and an emerging core of defense-tech product IP. The consolidated numbers only make sense once you separate these. (I)

Where the moat is broad but shallow (the 44%-NS&D core). For the largest, cost-plus/T&M labor book, the advantage is incumbency and clearances — real switching costs (incumbents win most re-competes on cleared staff and mission knowledge; losing an incumbent risks program disruption) but shared with every peer and expressed in a merely-ordinary 10.0% segment margin. This is a good staff-augmentation position, not a differentiated one — closer to a “cleared body shop” than a technology moat. (I) It is defensible against newcomers, contestable against CACI/SAIC/GDIT.

Where the moat is deep and financially visible (the profit engine).

• QTC / managed health — the crown jewel. Leidos runs a national footprint of health clinics performing VA medical-disability and behavioral-health exams under fixed-unit-rate (FFP) contracts, and has reduced the VA’s backlog of veterans awaiting exams by ~60% (F, Q4-FY25 call). The moat here is real: accumulated process/data advantage, a physical clinic + provider network, deep VBA relationship, and a scale/efficiency flywheel where doing exams faster/cheaper keeps the savings — producing a 23.7% segment margin, ~57% of company operating income (F). This is the one place the moat unambiguously shows up in a financial outcome that would deteriorate without it. (I)
• FAA air-traffic automation. Leidos is the incumbent developer/integrator of U.S. (and multiple foreign) air-traffic-control automation systems (ERAM lineage) — a decades-long, safety-certified, extreme-switching-cost position that is among the hardest re-competes in GovCon to dislodge. (F/I)
• Defense-tech product IP (Defense Systems, rising). ALPS/Marado passive radar (highlighted in the Golden Dome architecture; a $2.2B ABADS-MD award), IFPC air-defense, maritime autonomy (Seahawk MUSV — the Navy’s only operationally deployed medium USV, built on Gibbs & Cox naval architecture), and hypersonic structures. These are genuinely product-like, higher-barrier and margin-accretive as they enter production (Defense margin +680bps in Q4-FY25). This is where a new durable advantage could compound — differentiated payloads/sensors are far harder to re-compete away than labor. (F/I)

Where it is weak — the central skeptical points. (1) The moat is concentrated in one customer relationship. The QTC health engine that drives most of the profit is a single-customer (VBA), re-compete-exposed franchise — and the re-compete is live: a “fourth vendor” has entered the VA exam market with “possibility of a work-share reallocation,” and an RFP/re-bid is expected mid-2026 (F, Q4-FY25 & Q1-FY26 calls). Management insists volumes keep rising and margins stay above 20%, but “typically re-competes, you gotta sharpen the pencil” (analyst, Q4 call) — this is the single largest moat-durability question in the name. (I) (2) The differentiation is partly bought, and tangible book is negative. Like CACI, Leidos is a roll-up (IS&GS, Dynetics, Gibbs & Cox, 1901 Group, QTC, Kudu, Entrust); goodwill + intangibles exceed equity, so tangible common equity is negative (F, DATA_BRIEF). (3) The 44%-flagship earns only 10% — most of the company is not differentiated.

Moat-to-financial-outcome test. Does the moat show up where it should? Yes, better than CACI does. Leidos earns ROIC ~14–16% (FY25 ~16%) — a genuine ~600–700bp spread over an ~8–9% WACC, driven almost entirely by the high-margin Health/product franchises — versus CACI’s ~10% ROIC that merely hugs its cost of capital. That is the sharpest competitive distinction: Leidos’s acquired/incumbent advantages actually lift returns on invested capital; CACI’s largely do not. But the spread is carried by the concentrated Health book, so the moat’s durability = the QTC re-compete outcome. (I)

Direct comparison to peers.

• vs. CACI (~$8.6B, ~75% DoD, pure defense-tech, ~10% ROIC): CACI is a purer, more defense-technology-concentrated play that “won the DOGE regime shift” on ~75% DoD mix but earns only cost-of-capital returns. Leidos is 2x the size, more diversified (49% DoW+IC vs 75%), higher-returning (~16% vs ~10% ROIC), and carries a higher-margin health/product core — but is more exposed to civil/efficiency pressure and to a single health-customer re-compete. (I)
• vs. Booz Allen (~$11.2B, civil-consulting-heavy, DOGE-hit): Leidos is less advisory, less DOGE-exposed, larger, but lower-margin in its labor base than BAH’s historically premium consulting book.
• vs. SAIC / GDIT / Parsons: Leidos is the scale leader and, uniquely, holds the QTC health and FAA franchises none of the pure IT-services peers replicate.

Verdict (Competitive Position): A durable but narrow and concentrated advantage — genuinely better than the median GovCon prime, but not a wide moat. Leidos has what most peers lack: two hard-to-dislodge civil franchises (QTC health, FAA) and an emerging defense-tech product core that together push ROIC to a real ~600bp spread over WACC. But ~44% of the company is undifferentiated cleared labor, the profit is dangerously concentrated in a single re-compete-exposed health customer, and the differentiation was substantially bought (negative tangible book). The competitive position is good, not great, and its durability rests disproportionately on the 2026 VA-exam re-compete.

5. Growth History and Forward Opportunities

The record. Revenue compounded from $11,094M (FY2019) to $17,174M (FY2025), a ~7.6% CAGR (F). But the quality of that growth is mixed on two axes — organic-vs-acquired, and revenue-vs-EPS.

Organic vs. acquired. Much of the multi-year growth was acquired: the transformational IS&GS deal (2016, ~$5B) predates the window but set the base; Dynetics (2020, ~$1.65B defense-tech), 1901 Group (2021, IT), Gibbs & Cox (2021, ~$380M naval architecture) built the FY20–22 step-ups; and recently Kudu Dynamics (2025, cyber, ~$300M price) and Entrust Solutions Group (March 2026, energy-infrastructure engineering, $2.4B all-cash — the driver of the ~$1.7B Q1-FY26 debt jump flagged in the data brief) (F). Underlying organic growth is low-to-mid single digits: FY2025 revenue +3.1% (~4% normalized for the extra 2024 week and the 6-week shutdown), Q1-FY2026 +3% organic (F). So the durable organic rate is ~3–5%, not the ~7.6% headline. (I)

Revenue vs. EPS — the NorthStar margin story. The high-quality part of the growth is not the top line — it is margin expansion and buybacks. Operating margin rose from 7.7% (FY2019) to 12.3% (FY2025); adjusted EBITDA margin hit 14.1% in FY2025 (+120bps YoY, above the “high-13s” guide), on “six consecutive quarters of positive net EACs” and technology-driven efficiencies (F). Combined with retiring 4.4% of the share count in FY2025 (~$0.50 of EPS), this drove non-GAAP EPS +17% (to $11.99) on +3% revenue (F). This is the core of the NorthStar 2030 strategy — five growth pillars (space & maritime; energy infrastructure; digital modernization & cyber; mission software; managed health), a “faster, leaner, more focused” operating model, and scale-leverage via technology/AI insertion. The EPS growth has been genuinely high-quality; the revenue growth has been ordinary. (I)

Backlog coverage. Total backlog $49.0B (~2.9x revenue), funded $9.7B (~7 months) at 2026-01-02 (F) — but note management changed the backlog policy in FY2025 to include sole-source IDIQ task orders, inflating unfunded backlog by $4.8B (F), so the YoY backlog rise partly reflects an accounting change, not pure bookings. The tell to watch is by-segment: Health & Civil total backlog fell to $10.4B from $12.2B (unfunded dropped $3B) even as its funded backlog nearly doubled — consistent with the VA-exam re-compete overhang and volume normalization. (F/I) FY2025 book-to-bill was ~1.0x (Q3/Q4 each 1.3x, but Q1-FY26 only 0.8x / 1.1x TTM) — award momentum is choppy on procurement timing. (F)

Forward drivers. (1) Defense-tech production ramp — ALPS/passive radar ($2.2B ABADS-MD), IFPC air-defense, small cruise missile (AGM-190A, “thousands… this decade”), maritime autonomy (MUSV), all moving from development into higher-margin production; management earmarked a CapEx triple to ~$350M in 2026 to fund production capacity and classified facilities. (2) Managed-health expansion beyond VA exams — Military OneSource ($456M directed award), My Service Treatment Record AI pilot, behavioral and rural health — an attempt to diversify the health engine away from single-customer VBA dependence. (3) Energy infrastructure — Entrust lifts the pipeline ~230% (to ~$10B) into a fast-growing grid/utility market. (4) IC/cyber — classified digital-infrastructure spend +4–5%/yr; total cyber pipeline ~$24B post-Kudu. (5) AI-as-accelerant productivity/margin story. (F, both calls)

Growth risks. (1) The VA-exam re-compete (mid-2026 RFP) + fourth-vendor work-share reallocation — the single biggest threat to the profit engine; a share loss or margin reset in a 23.7%-margin book that is ~57% of operating income would swamp any top-line growth. (2) Volume normalization in QTC as the VA backlog is worked down (Health is guided flattish for 2026 with margins down “a little”). (3) CR/shutdown award air-pockets (Q1-FY26 book-to-bill 0.8x; Q2 guided as the “low point”). (4) DOGE/efficiency pressure on civil work. (5) Margin-expansion maturity — after 460bp of operating-margin gains, the incremental NorthStar margin runway is narrower, so EPS growth must lean more on top-line and buybacks. (I)

Verdict (Growth): Medium-quality growth — high-quality in earnings, ordinary and partly-bought in revenue, and increasingly hostage to one re-compete. The NorthStar margin-and-buyback engine has been excellent (EPS +17% on +3% revenue), but organic revenue is only ~3–5%, much of the multi-year top-line was acquired (Entrust/Kudu the latest), the margin-expansion runway is maturing, and the forward story depends disproportionately on defending and diversifying the concentrated Health book while a live VA-exam re-compete and a fourth vendor hang over it. Real, but neither cheap-quality nor low-risk.

6. Financial Quality

The Q1-FY2026 debt step-up — resolved

FACT. Total borrowings rose from $4,648M (FYE 2026-01-02) to $6,034M of long-term debt at Q1-FY26 (2026-04-03), plus $300M of commercial paper drawn in the quarter — the total-debt figure of ~$6.94B in the data brief. The increase is entirely acquisition financing, not a buyback or refinancing:

• FACT. On March 2, 2026, Leidos, Inc. (the operating subsidiary) issued $600M of 4.100% senior notes due 2029 and $800M of 5.000% senior notes due 2036 — $1.4B gross, ~$1,387M net proceeds after underwriting/expenses (8-K 2026-03-03; 10-Q Q1-FY26 cash flow: “Proceeds from debt issuance 1,397”). The notes explicitly pre-funded “a portion of the consideration payable in connection with the proposed acquisition of … ENTRUST.” A customary $1.4B 364-day bridge facility was arranged as backstop and was not drawn.
• FACT. On March 27, 2026, Leidos completed the acquisition of KENE Parent, Inc. (“Entrust”) for a base purchase price of $2.4 billion in cash (recorded at $2,385M after preliminary adjustments) (8-K 2026-03-30; 10-Q Note on Acquisitions). Entrust is “an engineering firm that provides infrastructure design, grid modernization and program management services primarily to electric, gas and pipeline utilities,” folded into the Homeland/energy-infrastructure book.
• FACT. Preliminary purchase-price allocation: total identifiable net assets $637M; goodwill $1,748M; intangible assets $564M — i.e., ~73% of the price is goodwill and ~97% is goodwill + intangibles. Cash acquired $47M, receivables $162M.
• FACT. Funding mix: $1,387M new notes + $300M commercial paper + ~$651M of balance-sheet cash (cash fell $1,108M → $457M) covered the ~$2.4B outlay.

Resulting leverage (FACT/INTERPRETATION). Q1-FY26 net debt ≈ $6.94B − $457M cash ≈ $6.48B, versus $3,540M at FY25 year-end. Against TTM EBITDA of ~$2.4B, reported net-debt/EBITDA rose from ~1.5x (YE) to ~2.7x (before any Entrust EBITDA contribution; pro-forma somewhat lower). The credit agreement caps adjusted total-debt/EBITDA at 3.75x, stepping up to 4.50x for the four quarters following a material acquisition — so LDOS remains comfortably inside covenant, and management retains investment-grade headroom. This is a deliberate, financeable step-up in leverage to fund a $2.4B deal, not distress.

Revenue growth & composition (FACT). Revenue compounded from $11.09B (FY2019) to $17.17B (FY2025), a ~7.6% CAGR — a blend of organic wins and the 2020–21 acquisition wave (Dynetics, 1901/IS&GS, Gibbs & Cox). Growth has decelerated sharply at the top line: FY2025 revenue rose only +3% ($16.66B → $17.17B), and book-to-bill “exceeded 1.0” (CEO letter, DEF 14A 2026-03-19) — adequate but not a growth story. This is a mature, ~75%+ U.S.-government-funded services business; the investment case is not top-line but margin and cash conversion. Revenue is overwhelmingly recurring/contractual (multi-year IDIQ, cost-plus, T&M, and fixed-price task orders) with ~$48B of total backlog across the four FY2025 segments (10-K FY2025 segment backlog table: National Security & Digital $26.3B, Health & Civil $12.2B, Commercial & International $4.4B, Defense Systems $5.6B).

Margin trajectory — the NorthStar story (FACT). Operating margin has expanded materially:

(ROIC.ai / 10-K; FY2023 op income excludes the impairment noise below.)

INTERPRETATION — is the 8.4%→12.2% ramp durable, or mix/one-time? It is mostly structural, partly mix, and not one-time — but likely near a ceiling. Drivers: (i) disciplined program execution and overhead reduction under the NorthStar 2030 plan; (ii) runoff of legacy low-margin, lower-value contracts and a mix shift toward higher-margin Health (QTC medical/disability exams, ~20%+ segment margin) and digital/software content; (iii) improved contract selectivity. None of these is a single non-recurring gain (FY2025 did include a small ~$28M pension/other item, immaterial to the trend). The caution: the margin ramp is partly powered by the very Health book now under recompete/volume pressure (see ), and the incoming Entrust (utilities engineering) and any commercial mix could be lower-margin. Two-plus years of doubling operating margin is impressive, but the incremental gains from here are harder — management’s original NorthStar “8%+” op-margin target was blown past long ago, and the market had priced continued expansion (the reason the de-rating stings).

Free cash flow & conversion (FACT). The model’s best feature. FY2025: CFO $1,750M, capex only $125M (~0.7% of revenue — genuinely asset-light), FCF ~$1,625M (~$12.70/share). CFO/net-income conversion was 1.21x (CFO $1,750M vs. GAAP NI $1,448M) — high quality, no accrual-earnings mirage. Multi-year CFO: $1,187M (FY23) → $1,435M (FY24) → $1,750M (FY25), tracking the margin ramp. Capex intensity is a structural advantage of a labor-based services firm: FCF ≈ 93% of EBIT.

SBC & dilution (FACT). Stock-based comp is $95M (FY25), up from $85M (FY24) and $77M (FY23) — only ~0.55% of revenue and ~5.8% of FCF, immaterial and not masking cash economics (contrast software peers). Diluted share count has fallen from ~143M (2019) to 126.4M (FY25) — buybacks more than offset dilution.

ROIC vs. WACC — the honest number (FACT/INTERPRETATION). ROIC.ai computes FY25 ROIC at ~16.1% (FY24 14.4%); against an estimated WACC of ~8–9%, LDOS earns a ~7-point positive spread — real, modest value creation, consistent with a competent (not exceptional) GovCon franchise. ROE of ~36% (FY25) is flattered and should not be read as business quality: it sits on a thin, buyback-shrunken, and now negative-tangible equity base and is levered. ROIC ~14–16% is the number that survives the leverage/buyback adjustment — the same pattern flagged in the CACI peer report (ROIC≈WACC-plus, ROE inflated by capital structure).

Balance sheet & the negative-tangible-book flag (FACT). At FY25 year-end: cash $1,108M, total debt ~$5,235M, net debt $3,540M, equity $4,962M — but goodwill $6,342M + intangibles $458M exceed total equity, so tangible common equity is negative ~−$1.84B. Post-Entrust (Q1-FY26), goodwill rises to ~$8.09B and intangibles to ~$1.02B against $5,064M equity, deepening TCE to ~−$4.05B. This is the signature of a serial acquirer/roll-up (as with CACI): book equity is an accounting residue of prices paid for acquired businesses, not tangible net worth. It is not a solvency issue for a cash-generative services firm, but it means (i) the balance sheet offers no downside cushion, and (ii) any future impairment (the SES precedent) hits reported equity directly.

Other QoE items (FACT):

• Pension: essentially fully funded — the U.S. defined-benefit plan was underfunded by only $1M at both year-ends (10-K FY25). No hidden pension overhang (unlike many legacy industrials).
• Non-GAAP wedge is modest. Leidos leans on “Adjusted EBITDA” / “Adjusted EBITDA margin” as its headline non-GAAP metric; intangible amortization is only ~$130M (~$0.80/share after tax), so the GAAP-to-adjusted EPS gap is small — GAAP diluted EPS $11.14 is close to economic reality. This is cleaner than CACI, whose adjusted-vs-GAAP wedge is large.
• Receivables: Q1-FY26 receivables jumped $2,708M → $3,028M; Entrust added $162M, leaving a ~$158M organic build — worth monitoring DSO but not yet a flag.

Verdict (Financial Quality): Yes — economics have improved with scale, but the easy gains are behind and quality rests on cash, not the balance sheet. LDOS converts a mature, low-growth revenue base into ~$1.6B of near-unencumbered FCF at ~0.7% capex intensity, with clean accounting, negligible SBC, and a genuine ~7-point ROIC-over-WACC spread. The 7.7%→12.2% operating-margin ramp is largely structural, not one-time. But top-line growth is only ~3%, incremental margin expansion is getting harder, ROE overstates quality (leverage + negative tangible book), and the highest-margin book (Health) is the one now at risk. Good business, plateauing.

7. Capital Allocation

M&A history — a mixed, occasionally value-destructive record (FACT/INTERPRETATION). Leidos is a serial acquirer, and the ledger is uneven:

• IS&GS (Lockheed Martin, 2016, ~$5B Reverse Morris Trust) — the transformational deal that roughly doubled the company; broadly regarded as successful (scale, IT-services franchise).
• Dynetics (2020, ~$1.65B cash) and Gibbs & Cox (2021, ~$380M) — defense-systems/naval capability; retained.
• Security Detection & Automation from L3 (2020, ~$1.0B) → became the SES reporting unit, which was impaired in FY2023: a $596M non-cash goodwill impairment plus $91M of asset impairments (~$687M total), leaving only $308M of SES goodwill (10-K FY2023). This is hard evidence of overpayment/value destruction — the price paid for the airport/port detection business proved unrecoverable.
• Kudu Dynamics (Savanna Industries, 2025, ~$293M) — cyber/offensive-security tuck-in, immaterial in size.
• Entrust / KENE (2026, $2.4B, ~73% goodwill) — the largest deal since IS&GS, into utilities/grid-modernization engineering. INTERPRETATION: paying 73% of the price as goodwill for a commercial-adjacency engineering firm, debt-funded, is precisely the profile that produced the SES impairment; the burden of proof is on management. No purchase multiple was disclosed.
• Portfolio cleanup (FACT): In April 2026 Leidos agreed to contribute the Security Enterprise Solutions + Industrial Automation (SES/IA) business into a JV with Analogic/Altaris, taking a 41.5% equity stake (8-K 2026-04-15; expected 2H2026). This deconsolidates the impaired, lower-margin detection business — a sensible admission that SES was better owned in partnership than outright.

Buybacks — large and counter-cyclically timed on the way down (FACT). Repurchases of stock and other: $246M (FY23) → $906M (FY24) → $944M (FY25) (~$882M of it open-market authorization spend). Buybacks accelerated as the stock rose through 2024–25 (a mixed timing signal — much was bought in the $130–180 range) but Q1-FY26 repurchases were cut to $243M (from $528M in Q1-FY25) to conserve cash for Entrust. INTERPRETATION: the reduced-share-count math (143M→126M) is accretive, but a chunk of FY24–25 buyback was executed near what proved to be a cyclical price peak — average execution was not opportunistic. Watch whether management leans back in aggressively at today’s ~9–10x P/E (that would be genuinely value-additive per-share).

Dividend (FACT). Raised to $0.43/quarter (from $0.40 in late 2025); FY25 declared $1.63/share, $211M paid — a ~13% payout of FCF, conservative with ample room to grow. ~1.6% yield at spot.

Debt & per-share value (INTERPRETATION). Management is deploying the balance sheet — net leverage stepped to ~2.7x for Entrust — while maintaining IG metrics and covenant headroom. The per-share test is favorable on FCF (fewer shares, growing FCF/share to ~$12.70) but hostage to whether Entrust earns its cost of capital; the SES precedent is the cautionary counter-evidence.

Insider behavior — no conviction buying into a 46% crash (FACT). Reviewing the Form-4 corpus (MANIFEST: 554 Form 4s; 177 filings fetched and parsed for the 2024-11 → 2026-07 window):

• Exactly one open-market purchase (code P) in ~20 months: Director Noel B. Geer bought 2,000 shares @ $161.13 on 2024-11-20 (~$322K). That is the sole conviction buy across the entire peak-and-crash window.
• CEO Tom Bell and CFO Chris Cage made zero open-market purchases — their activity is entirely routine: RSU/PSU grants (code A), tax-withholding on vesting (F, e.g., Bell 18,907 sh withheld @ $173 on 2026-02-12), and option exercises (M). Bell’s Feb-2026 grants totaled ~65,000 shares.
• Discretionary sales were small (18 code-S sales ≈ 57,900 shares ≈ ~$10M total), concentrated in Sector Presidents (Stephen Hull ~$5.9M near the $178 peak Aug–Sep 2025; Elizabeth Porter selling from $192 in Jan-2026 down to $159 in Apr-2026) — planned/diversification, not a red flag.
• INTERPRETATION: The telling signal is the absence of buying — despite the stock halving to ~9–10x earnings, no officer or director stepped in. That is a mildly negative-to-neutral tell: insiders are not signaling that the sell-off is a gift.

Comp alignment — well-designed (FACT). DEF 14A 2026-03-19: the annual cash incentive is weighted Revenue 30% / Operating Cash Flow 30% / Adjusted EBITDA Margin 40% (±20% individual modifier) — i.e., 70% on margin and cash, only 30% on top-line, discouraging revenue-for-its-own-sake empire-building. Long-term PSUs pay on 50% cumulative Adjusted EBITDA + 50% relative TSR vs. a peer group (threshold 30th / target 50th / max 120% of target & top-quartile). Target total direct comp is set at ~median. This structure genuinely rewards the margin/FCF/relative-return outcomes shareholders care about — a positive.

Verdict (Capital Allocation): Adequate, not distinguished — good discipline and shareholder-friendly returns, offset by an uneven M&A record and buybacks bought near the peak. The dividend, share-count reduction, clean incentive design, and the SES/IA JV cleanup are all defensible. But the FY2023 SES impairment is concrete evidence of overpayment, the new $2.4B/73%-goodwill Entrust deal carries the same risk profile, and management repurchased heavily near a cyclical peak while declining to buy the subsequent crash. Per-share value has been created historically (FCF/share, share count), but the forward record hinges on Entrust not becoming SES 2.0.

8. Changes and Headwinds — Last Two Years

CEO transition & NorthStar (FACT). Roger Krone retired; Tom Bell became CEO in May 2024 (ex-Rolls-Royce North America / Boeing Defense). Bell launched the NorthStar 2030 strategy and drove the operating-margin ramp (8.4%→12.2% across FY23–FY25). INTERPRETATION: the margin transformation is the defining positive of the Bell era and the reason the stock tripled into November 2025; it is also why the 2026 de-rating is so violent — the market had extrapolated continued expansion.

Segment reorganization (FACT). Effective FY2025, the old four segments (Defense Solutions / Civil / Health / Commercial) were restructured into National Security & Digital; Health & Civil; Commercial & International; Defense Systems. This reshuffles reporting and complicates like-for-like margin comparison, but does not change the economics.

The specific de-rating driver — Health portfolio pressure (FACT/INTERPRETATION). The stock fell ~46% from its $197.91 peak (2025-11-04) to ~$106 (7/17/2026) — a 2026 event. The distinct LDOS catalyst (on top of sector-wide DOGE/appropriations fear) is pressure across the Health portfolio: the QTC/VA medical-disability-and-behavioral-health-exam franchise (~20%+ segment margin, the crown jewel that powered the margin ramp) faces volume normalization and recompete risk. Sell-side flagged this explicitly (BofA downgrade to Neutral $125 on 6/17/2026, “rising pressure across the Health portfolio”). INTERPRETATION: because Health is the highest-margin book and disproportionately drove the NorthStar margin gains, any de-rating there directly threatens the central bull thesis — hence a de-rating larger than lower-margin GovCon peers.

Macro / GovCon overhang (FACT). The broader 2025–26 sell-off reflects DOGE-driven contract-scrutiny fear, continuing-resolution/appropriations uncertainty, and OTA/procurement-reform noise (10-K FY25 risk factors) — the same overhang that repriced CACI, BAH, SAIC, V2X (LDOS’s factor peers).

Portfolio & balance-sheet moves (FACT):

• Entrust ($2.4B, closed 3/27/2026) — debt-funded push into utilities/grid-modernization engineering (energy-transition adjacency), 73% goodwill; the source of the ~$1.7B Q1 debt increase.
• SES/IA JV with Analogic/Altaris (agreed 4/14/2026, ~2H2026 close) — contributing the impaired detection/automation business for a 41.5% stake; a portfolio-quality upgrade.
• DHL UK defense-logistics alliance (7/17/2026) and Rune Technologies military-logistics collaboration (7/9/2026) — small partnership/BD moves, not financially material yet, signaling a defense-logistics and commercial-international push.
• Kudu Dynamics (2025, ~$293M) — cyber tuck-in.

Verdict (Changes & Headwinds): Net weakening of the near-term thesis, but with a cleaner portfolio. The positives — a credible CEO, a real (if plateauing) margin transformation, and the SES/IA cleanup — are outweighed near-term by the collision of (i) top-line deceleration to ~3%, (ii) the specific Health-portfolio recompete/volume threat to the highest-margin book, (iii) sector-wide DOGE/appropriations pressure, and (iv) a leverage step-up to ~2.7x to fund a goodwill-heavy Entrust deal that must still prove it is not another SES. The thesis has moved from “margin-expansion compounder” toward “cheap, cash-generative GovCon at a trough multiple with a Health-margin question mark.”

9. Risk Analysis

Leidos is a low-catastrophic-risk, high-idiosyncratic-headline-risk business: a $17B-revenue, ~75%-US-government prime contractor with investment-grade credit, ~$1.6B annual free cash flow, and a ~46% drawdown driven almost entirely by one segment’s outlook (Health) plus sector-wide DOGE/appropriations fear. The risks below are ranked by their bearing on the thesis, with the Health/VBA disability-exam recompete-and-volume risk as the single dominant swing factor — it is both the market’s stated de-rating catalyst (BofA downgrade, 6/17/2026) and the largest concentration of segment profit.

9.1 Risk Matrix

9.2 Catastrophic-loss / total-loss assessment

INTERPRETATION. The odds of a catastrophic or total loss of capital are low. Leidos is a government-backed, cash-generative prime with (i) ~$1.6B annual FCF and >1.1x FCF/NI conversion (FY25 CFO $1.75B on NI $1.45B), (ii) investment-grade credit and self-deleveraging leverage (~2.4x net), (iii) an asset-light model (capex ~0.7% of revenue historically), and (iv) revenue backed by multi-year, mostly cost-plus/fixed-unit-rate government contracts with >90% recompete win rates. The realistic downside is an earnings and multiple reset — a Health/VBA volume-and-margin step-down, a goodwill write-down, and a de-rating that has already largely occurred (P/E at the 1.7th percentile of its own 10-year range) — not insolvency or business failure. The tangible-common-equity deficit is an accounting artifact of the LDOS/IS&GS/Dynetics roll-up (goodwill $6.34B), not a liquidity constraint; it matters for how one values the business (cash flows, not book), not for going-concern risk. A true total loss would require a simultaneous, permanent collapse of US defense/IC/health procurement — not a base-case scenario.

Verdict: Risk is skewed to earnings-power reset and headline volatility, concentrated in Health/VBA, not to permanent capital impairment. The stock has already priced a great deal of the reset; the asymmetry now hinges on whether the Health reset is a one-year trim or a structural de-rating (see ).

10. Valuation

No price target. No BUY/SELL. Multiples and embedded-expectations only.

10.1 Where the multiple sits — cheapest in its own history

At $106.48, LDOS trades at extremes of its own decade-long valuation range (AZI own-history percentiles): P/E 9.75x → 1.7th percentile (cheapest ever), P/S 0.80x → 15.4th, P/B 2.72x → 26.9th, composite 14.7th. On trailing metrics: TTM EPS $10.92 → P/E 9.75x; FY25 FCF $1.625B → P/FCF ~8.4x (FCF/sh ~$12.70); ~1.6% dividend yield ($1.72 annualized, raised late-2025). (FACT — AZI valuation_index; ROIC valuation multiples.)

Important correction to the snapshot EV/EBITDA and FCF-yield figures. The ROIC enterprise-value snapshot (mkt cap $19.6B, EV $26.1B, EV/EBITDA 10.9x, ~8% FCF yield) is dated to the Q1 print (~late-April/May-2026, price ~$150+) and is stale. Recomputed at spot $106.48 (~129M diluted shares → mkt cap ~$13.7B; net debt ~$5.8B → EV ~$19.5B):

INTERPRETATION: the correction matters — at spot, LDOS is not merely “cheap on P/E, mid-pack on EV/EBITDA”; it is ~8x EV/EBITDA and an ~11-12% trailing FCF yield, cheaper than the higher-margin services peers on nearly every axis. The FY23 GAAP EPS ($1.44) is distorted by the $687M goodwill impairment + 48% tax and must not anchor the P/E history; normalized FY23 EPS was ~$8, i.e., the multiple is on genuine earnings power.

10.2 GovCon comp table (ROIC TTM, at each name’s recent price)

FACT — ROIC get_valuation_multiples, TTM, dated 2026-03-31/04-30. INTERPRETATION on notes.

Read: on P/E, LDOS (9.8x) is the cheapest in the group. On EV/EBITDA at spot (~8.2x) it is at/below SAIC and KBR despite carrying the highest EBITDA margin (~14% vs peers’ 9-11%) — a services/tech GovCon earning defense-products-like margins yet priced below commodity IT-services peers. CACI (16x EV/EBITDA, the closest factor-peer at 0.94 correlation) and LHX (22x) show what the group pays for a “products/tech scaling” narrative — precisely the NorthStar-2030 story LDOS is telling but is receiving zero credit for. The gap between LDOS’s ~8x and CACI’s ~16x EV/EBITDA is the crux of the mispricing-vs-value-trap debate: either LDOS’s margin is peaking/Health is breaking (justifying the discount), or the market is extrapolating one segment’s reset across a diversified, higher-margin book.

10.3 FY2026 guidance (raised at Q1, 5/5/2026)

FACT (mgmt guide): Revenue $18.0-18.4B (raised $500M, primarily Entrust); adj-EBITDA margin “mid-13s” (~13.5%, i.e., ~$2.45-2.48B); non-GAAP diluted EPS $12.10-12.50 (raised $0.05); operating cash flow ~$1.8B; capex guided up to ~$350M (tripled, finite investment period) → implied FY26 FCF ~$1.45-1.6B; gross leverage 2.6x. Q2 flagged as the low point (growth/margin); back-half reacceleration expected; TTM book-to-bill 1.1x.

10.4 Embedded-expectations analysis — what $106.48 is underwriting

INTERPRETATION, with stated assumptions. Three lenses converge on the same conclusion: the price embeds roughly no long-term real growth.

1. Forward P/E. At the $12.30 guide midpoint, LDOS trades at ~8.7x forward EPS. GovCon services/tech have historically cleared 13-18x; LDOS’s own 10-year median is ~15-16x (implied by the 1.7th percentile). To justify only 8.7x, the market must believe forward EPS is unsustainable — i.e., that the $12.30 guide is a peak to be given back (Health reset + margin reversion).

2. Reverse DCF (perpetuity). With EV ~$19.5B, normalized FCF ~$1.6B, and a 9% WACC, the implied perpetual FCF growth rate is g ≈ 0.7-1.2% (solving EV = FCF·(1+g)/(WACC−g)). The market is pricing LDOS as a low-inflation, no-real-growth annuity — against a company guiding mid-single-digit revenue growth, IC/digital budgets growing 4-5%/yr (mgmt), and a Defense-products pipeline mgmt sizes at >$8B of forward awards.

3. FCF yield. An ~11-12% trailing FCF yield (10% even on the elevated-capex FY26) implies the market demands a mid-teens total return or expects FCF to decline. With FY25 buybacks of $882M + $211M dividends (~$1.1B, ~2/3 of FCF returned) and continued repurchases at trough (Q1 $200M), the shareholder-yield-plus-modest-growth math is the bull’s arithmetic.

What the market is pricing correctly: (i) Health/VBA faces genuine volume, share (4th vendor), and recompete uncertainty, and Health is disproportionately profitable — a real, thesis-relevant risk; (ii) FY25’s 12.2% op margin / 13.9% EBITDA margin sits at a cyclical/mix high, aided by incentive fees and one-offs (Q1 $15M insurance item) — capitalizing peak margin would be an error; (iii) sector-wide DOGE/appropriations/shutdown drag is real and near-term (Q2 the low point).

What the market may be pricing incorrectly: (i) extrapolating one segment’s reset into ~1% perpetual growth for a diversified, IC-weighted, 90%±recompete-win-rate book; (ii) ignoring the NorthStar margin structure that has already doubled op margin (7.7%→12.2%) and the Entrust/Defense-products growth optionality receiving zero multiple credit; (iii) treating post-Entrust leverage (2.4-2.6x, self-deleveraging, IG) as a balance-sheet risk rather than a temporary, cash-covered draw.

10.5 Scenario framework (illustrative; no price target)

Assumptions are explicit and illustrative; the spread across scenarios is driven ~80% by the Health/VBA outcome and margin durability. The “What Must Be True” falsification tests map directly onto these.

Verdict: Priced at the cheapest P/E in its history, ~8x EV/EBITDA, and an ~11-12% FCF yield, LDOS embeds ~1% perpetual growth — a valuation that is correct if Health/VBA is structurally impaired and margins revert, and materially too cheap if Health is a one-year trim within a diversified book still guiding mid-single-digit growth and returning ~2/3 of FCF to holders. The debate is not “cheap or expensive” — it is unambiguously cheap on every lens — but “cheap-and-broken (value trap) vs. cheap-and-mispriced.”

11. Variant Perception

11.1 Consensus belief

The market view is “cheap but broken / still de-rating.” LDOS was a ~$198 GovCon darling in Nov-2025 and has fallen ~46% into mid-2026 on a specific, credible catalyst: deteriorating Health-segment (QTC/VBA disability-exam) volume, a newly added 4th VA exam vendor diluting share, and an unresolved recompete — layered onto sector-wide DOGE/appropriations/services-skepticism. Consensus accepts the ~9-10x P/E as deserved because the crown-jewel, highest-margin book is resetting and FY25 margins looked like a peak. Tellingly, every published sell-side target sits above spot — Goldman $152, JPM $160, Truist $160, Citi $138, BofA $125, TD Cowen $115 (even the bear) vs. $106.48 — yet the stock keeps grinding lower. That configuration (“targets above, price below, no catalyst”) is the fingerprint of a name the Street believes is cheap but has no reason to bounce until the Health/VBA overhang clears.

11.2 Factor-positioning read (Momentum/factor overlay)

FACT (FactorsToday / AZI): Classic falling knife — 1-year return −32.0% (Sharpe −1.10), 6-month −67% annualized, max drawdown −49.5%, relative strength rs_12m −33%, rs_6m −44%. Yet beta is only ~0.45 and factor R² is low (0.12-0.19) — this is a low-beta defensive that repriced on idiosyncratic, company-specific news, not a market/beta-driven decline. It screens simultaneously as deep value (P/E 1.7th percentile) and deep-negative momentum — the textbook value-vs-momentum standoff. INTERPRETATION: the tape says the de-rating is not obviously finished (no positive momentum inflection, no catalyst before VBA industry-day clarity), while the factor/value screen says the price has overshot fundamentals. The knife is still falling on price; the valuation is already at capitulation levels.

11.3 Strongest bull case

A diversified, IC-weighted prime earning the group’s highest margins is being priced as a no-growth annuity because of one segment’s headline. Concrete supports: (i) mgmt states Health exam volume “remained high through Q1” and the VA is “challenging the system to burn off backlog”; (ii) Health is broadening beyond VBA into managed-health (the $456M Military OneSource directed award, My Service Treatment Record pilot, behavioral/rural health) with margins mgmt insists stay “>20%”; (iii) NorthStar has already doubled op margin (7.7%→12.2%) and management guides sustained mid-13s EBITDA margin; (iv) Defense products are scaling to real production (SCM/AGM-190A “thousands this decade,” ALPS on ABADS-MD $2.2B, MUSV/Seahawk operationally deployed), with >$9B Defense-Tech awards in 15 months; (v) IC/digital budgets grow 4-5%/yr and AI is framed as an accelerant of the entrenched digital-infrastructure position; (vi) ~11-12% FCF yield funding ~$1.1B/yr of buybacks+dividends at trough. Re-rate from 9x toward the 13-15x mid-cycle and the math is powerful.

11.4 Strongest bear case

The VBA disability-exam book is a fixed-unit-rate contract up for recompete with a new 4th vendor structurally diluting LDOS’s share, and Health — ~1/4 of revenue — throws off an outsized ~35-40% of segment operating profit at 20%+ margins. Even a “modest reset” in the highest-margin book, compounded by a lost or re-priced recompete, cuts group EPS and margin more than the flat top-line suggests. FY25’s 12.2% op margin is a peak flattered by incentive fees and one-offs; services work is exactly what DOGE/AI commoditizes; the balance sheet carries $6.3B debt and negative tangible common equity (goodwill $6.34B > equity $4.96B) from a serial roll-up with an impairment precedent (FY23 $687M). At 9x the stock isn’t cheap enough if normalized EPS is really ~$10 and the multiple stays de-rated — the definition of a value trap.

11.5 The 3-5 assumptions that matter most (and what falsifies each side)

11.6 Is consensus offsides?

INTERPRETATION. Consensus is directionally right on the risk but arguably overshooting on the price. The Health/VBA concern is legitimate and thesis-central — the bears have identified the correct single variable. But the magnitude of the de-rating (to ~1% embedded perpetual growth, cheapest-ever P/E, ~8x EV/EBITDA on the highest-margin book in the group) prices a structural impairment of the whole company, when management’s own data (Q1 volumes high, book-to-bill 1.1x TTM, IC +4-5%) and the sell-side’s own above-spot targets suggest a segment reset, not a franchise break. The setup is a genuine value-vs-momentum standoff: the factor tape says “knife still falling, no catalyst,” the valuation says “capitulation.” The resolution is almost entirely binary on Health/VBA — which is exactly why the stock is stuck below every target price. Consensus is offsides only if the Health reset proves to be a one-year trim; if it is structural, the cheap multiple is correct. That single fork, not the aggregate GovCon narrative, is where the variant view lives.

12. Fact vs. Interpretation Table

13. Open Questions

1. The VA disability-exam re-compete (the single most important unknown). What are the terms and timing of the mid-2026 RFP? Does the fourth vendor take work-share, and on what basis (price, capacity, set-aside)? Can Leidos hold both its volume and its ~20%+ Health margin through a re-bid, or does “sharpening the pencil” reset the economics of the crown jewel? Every scenario in turns on this.
2. Is 12.2% operating margin the normalized level or a peak? How much of the FY2024–25 ramp is durable structural mix (NorthStar execution, legacy-contract runoff) versus incentive/award fees and one-offs that revert? Two to three quarters of segment margins ex-one-offs will tell.
3. Will Entrust be accretive, or SES 2.0? No purchase multiple was disclosed on a $2.4B, 73%-goodwill, debt-funded deal into a commercial-adjacent engineering market. What return on invested capital does grid-modernization engineering actually earn inside Leidos, and how cyclical is utility capex?
4. Does defense-tech product revenue actually scale? The pipeline (ALPS/ABADS-MD $2.2B, small cruise missile, MUSV/Seahawk, IFPC) is large, but Q1-FY26 Defense margin fell to 8.3% on a fixed-price development delay. Do awards convert to booked, higher-margin production, or stay pipeline with EAC drag?
5. Why will management not buy the stock at 9–10x? Buybacks were heavy near the peak and cut to $243M in Q1 to fund Entrust; no insider bought the crash. Does the pace re-accelerate at trough valuations (genuinely value-additive), or does leverage constrain it?
6. How exposed is the ~57%-of-revenue cost-plus/T&M labor base to AI and FAR reform? Management frames AI as an accelerant; the bear case is that it deflates the commodity-labor book. Which shows up first in the numbers?

14. What Must Be True

For the bull case (cheap-and-mispriced) to be right:

• The Health/QTC franchise survives the re-compete roughly intact — Leidos retains its VA disability-exam share and holds Health segment margin at or above ~20% through and beyond the mid-2026 RFP. Falsification test: the re-compete resolves with a lost award, a material work-share reallocation to the fourth vendor, or a reported Health segment margin below ~18% in FY2026 prints. If that happens, the crown jewel is structurally impaired and the bull case is dead.
• 12–13% operating margin is a floor, not a peak — segment margins ex-one-offs hold through FY2026, EACs stay net-positive, and mid-single-digit revenue growth resumes in 2H26/2027. Falsification test: two consecutive quarters of operating margin reverting toward ~11% with no offsetting growth re-acceleration.
• The balance sheet deleverages and per-share compounding continues — net-debt/EBITDA falls back toward ~2x within 18 months, Entrust earns its cost of capital, and buybacks resume at trough prices. Falsification test: a goodwill write-down on Entrust, or leverage stuck above ~3x with buybacks frozen.

For the bear case (cheap-and-broken / value trap) to be right:

• The VA re-compete cuts scope or price on the highest-margin book, dragging Health margin toward the mid-teens and resetting normalized EPS toward ~$10. Falsification test: the RFP resolves with Leidos retaining share and margin — at which point ~$12+ EPS at a 9–10x multiple is simply too cheap.
• FY2025 margins prove to be a cyclical/incentive-fee peak that reverts as NorthStar matures and AI/DOGE commoditize the cost-plus labor base. Falsification test: sustained mid-13s% EBITDA margin across FY2026 with positive book-to-bill.
• The roll-up keeps destroying value — Entrust follows SES into impairment, confirming management pays multiple for growth it cannot earn back. Falsification test: Entrust hits its revenue/margin plan with no write-down through FY2027.

The two cases are unusually cleanly separated: they resolve on the same small set of observable events, chief among them the mid-2026 VA disability-exam re-compete and the FY2026 Health segment margin line. That is what makes Leidos, at its cheapest-ever multiple, a genuine analyzable fork rather than a diffuse macro bet.

APPENDIX A — Standard Diligence Questionnaire

Leidos Holdings, Inc. (NYSE: LDOS) — 2026-07-17. Supplemental to the memo. Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked? The debate centers on three: (1) Is the Health/QTC/VA disability-exam franchise structurally impaired or facing a one-year trim? — the fourth-vendor entry and mid-2026 re-compete are the whole controversy. (2) Is 12.2% operating margin the new normal or a peak? — how much of the NorthStar ramp reverts. (3) Will the $2.4B Entrust deal earn its cost of capital, or become another SES impairment? Underneath: does a ~9.75x P/E on the group’s highest-margin, highest-ROIC prime price a value opportunity or a value trap.

Cyclicality & Earnings Nature

Cyclical high or low? Interpretation: Margins are at a cyclical/structural high (op margin 12.2% vs. 7.7% in 2019); revenue growth is at a low (~3% organic, dragged by CR/shutdown award timing). So earnings are near a high, growth near a low — an unusual split. External environment or internal actions? Both — margin gains are internal (NorthStar execution); the growth slowdown and de-rating are external (appropriations/CR/DOGE) plus the Health-specific re-compete. Revenue stability? High — ~$48–49B backlog (~2.9x revenue), multi-year IDIQ/cost-plus/fixed-price task orders, ~87% U.S. government, >90% recompete win rate. Stability is a defining feature; growth is the question, not durability of the base. Market size / direction? Large and growing in dollars — defense ~$893B, intelligence/digital budgets +4–5%/yr — but competed at the task-order level and subject to monopsony reprioritization.

Business Quality & Competitive Moat

Industry more or less competitive? Structurally consolidated at the prime tier (LDOS/GDIT/BAH/CACI/SAIC/Parsons) but competitively bid at the task-order level; FAR reform is widening competition to non-traditional entrants (Palantir, Anduril). Net: intensely competitive on price for commodity labor, less so for the high-barrier franchises. How profitable (ROIC/ROE)? Fact: ROIC ~14–16%, ROE ~36%. The honest number is ROIC ~14–16% — a genuine ~7-pt spread over WACC, better than CACI’s ~10%. ROE is flattered by leverage and negative tangible book. Industry profitability / barriers? Moderate; barriers (clearances, past-performance, DCAA accounting) protect incumbents as a class from newcomers but not from each other. A structurally capped, monopsony-customer industry. Easily understood? Yes at the segment level; the key subtlety is the bimodal profit structure (30% of revenue = ~57% of profit). Undermined by foreign low-cost labor? No — cleared, U.S.-person, on-shore work by regulation. Do brands matter? Not consumer brands; past-performance reputation and clearances are the functional equivalent. Switching costs? High on incumbent programs (mission knowledge, cleared staff, certification — especially FAA air-traffic and QTC health), lower on commodity IT/staff-aug.

Financial Condition & Balance Sheet

Assets not on the balance sheet? The QTC clinic/provider network and past-performance/relationship capital are undervalued on a goodwill-based book. Off-balance-sheet liabilities? None material; operating leases and a fully-funded pension (U.S. DB underfunded by only ~$1M). Conservatism of accounting? Clean — CFO/NI ~1.2x, modest non-GAAP wedge (~$130M intangible amortization), negligible SBC (~0.55% of revenue) — cleaner than most roll-up peers. CapEx-hungry? No — capex ~0.7% of revenue (~$125M); FY2026 capex is guided up to ~$350M for a finite production/facility investment.

Capital Allocation & Management

FCF and its use? ~$1.6B FCF; ~$1.1B/yr returned (buyback ~$882M + dividend $211M in FY2025), the rest to M&A and debt. Philosophy: shareholder returns + serial M&A, incentive-aligned to margin/cash/TSR. Recent acquisitions? Entrust ($2.4B, grid-modernization engineering, March 2026); Kudu Dynamics (~$293M cyber, 2025). Buybacks? Yes — 143M→126M shares since 2019, but much bought near the cyclical peak and cut to $243M in Q1-FY26 to fund Entrust. Issuing shares to insiders? Only routine RSU/PSU grants (~$95M SBC); not dilutive net of buybacks. Compensation? Well-designed — annual: Revenue 30% / OCF 30% / Adj. EBITDA margin 40%; PSU: 50% Adj. EBITDA + 50% relative TSR. Management motivation: Interpretation — credible operator (CEO Tom Bell since May 2024 drove the margin transformation), but no insider bought the 46% crash (one 2,000-share director buy in 20 months) — not signaling a gift.

Valuation & Market Data

ADR / MLP / K-1? No — U.S. C-corp common stock, NYSE. Dividend policy? ~$1.72/yr ($0.43/qtr, raised from $0.40 late-2025), ~1.6% yield, ~13% of FCF — conservative, growing. Profitability? See ROIC ~16%; FY2025 net margin 8.4%. Net income vs. CFO? CFO exceeds net income (~1.2x) — no accrual divergence; earnings are cash-backed.

Risks & Downside

What would cause the stock to decline (further)? A lost or re-priced VA disability-exam re-compete; Health segment margin breaking below ~18%; operating-margin reversion toward ~11%; an Entrust goodwill write-down; a prolonged shutdown/CR air-pocket. Catastrophic loss risk? Interpretation: Low — government-backed, investment-grade, ~$1.6B FCF, self-deleveraging, asset-light. Total loss? Very low — would require a permanent collapse of U.S. defense/IC/health procurement. The realistic downside is an earnings-and-multiple reset (much already priced), not insolvency; the negative tangible book is a roll-up artifact, not a liquidity constraint.

Recent News & Events

Environment changed recently? Yes — a ~46% de-rating (Nov-2025 to June-2026) on Health-portfolio re-compete fear plus sector DOGE/appropriations pressure; FY2026 guidance nonetheless raised at the Q1 print. Significant acquisitions? Entrust ($2.4B, closed 3/27/2026). Accounting-policy changes? FY2025 segment reorganization (and a further FY2026 re-cut moving FAA out of Health) — breaks segment comparability; a backlog-policy change added ~$4.8B unfunded backlog. Other recent changes? SES/IA contributed to an Analogic/Altaris JV (41.5% stake, ~2H2026); DHL UK defense-logistics alliance and Rune military-logistics collaboration (July 2026); CapEx tripling for defense-production capacity.

APPENDIX B — Source Appendix

Leidos Holdings, Inc. (NYSE: LDOS) — research date 2026-07-17. Primary sources first. Facts in the memo trace to these; management commentary is treated as hypothesis and validated against filings, financials, and third-party data.

Primary — SEC filings (EDGAR, CIK 0001336920)

• Form 10-K, FY2025 (fiscal year ended 2026-01-02), filed 2026-02-17 — business, four-segment structure & segment operating margins, contract-type & customer mix, backlog, risk factors, human capital, pension. https://www.sec.gov/Archives/edgar/data/1336920/000133692026000030/ldos-20260102.htm
• Form 10-Q, Q1-FY2026 (quarter ended 2026-04-03), filed 2026-05-05 — Entrust purchase-price allocation, debt issuance, segment margins, receivables.
• Form 10-K, FY2023 (ended 2023-12-29), filed 2024-02-13 — the $596M SES goodwill + $91M asset impairment (evidence of L3-detection overpayment).
• Form 10-K FY2024 / FY2022 / FY2021 — multi-year revenue, margin, cash-flow and share-count history.
• Form 8-K, 2026-03-03 — $600M 4.100% senior notes due 2029 + $800M 5.000% senior notes due 2036 (Entrust pre-funding); 364-day bridge backstop.
• Form 8-K, 2026-03-30 — completion of the KENE Parent, Inc. (“Entrust”) acquisition, $2.4B cash, closed 2026-03-27.
• Form 8-K, 2026-04-15 — agreement to contribute the SES / Industrial Automation business into a JV with Analogic/Altaris (41.5% stake).
• DEF 14A proxy, filed 2026-03-19 — executive compensation design (annual incentive: Revenue 30% / OCF 30% / Adj. EBITDA margin 40%; PSUs 50% cumulative Adj. EBITDA + 50% relative TSR); CEO letter (book-to-bill >1.0).
• Forms 3/4/5 (insider) corpus, 2024-11 → 2026-07 — open-market purchase/sale activity; the single director buy (Noel Geer, 2,000 sh @ $161.13, 2024-11-20) and the absence of CEO/CFO open-market buying.

Primary — earnings-call transcripts (via ROIC.ai)

• Q1-FY2026 earnings call, 2026-05-05 — raised FY2026 guidance (revenue $18.0–18.4B, non-GAAP EPS $12.10–12.50, OCF ~$1.8B, capex ~$350M, gross leverage 2.6x); Health exam-volume and fourth-vendor/re-compete commentary; segment margins; IC/digital budget growth.
• Q4/FY2025 earnings call, 2026-02-17 — NorthStar 2030, Health “above 20%” margin framing, VA backlog reduction ~60%, segment reorganization, book-to-bill.
• Q3-FY2025 earnings call, 2025-11-04 — the print coincident with the all-time-high share price.

Market & quantitative data

• Aggregated fundamental data — multi-year income statement, balance sheet, cash flow, profitability/credit/liquidity ratios, enterprise value, and valuation multiples for LDOS and comparables (CACI, BAH, SAIC, KBR, LHX); reconciled to SEC filings.
• Market price data — split/dividend-adjusted daily price history (five-year event map, 52-week range, moving averages, beta) and own-history valuation percentile ranks (P/E 1.7th, P/B 26.9th, P/S 15.4th, composite 14.7th).
• A quantitative factor model — ElasticNet factor loadings (Market beta ~0.45, low R²), risk-adjusted leaderboard (1-yr −32%, 6-mo −67% annualized, max drawdown −49.5%), relative strength, and factor-similar peers (CACI 0.94, V2X, BAH, SAIC, KBR).

Third-party / market

• Sell-side notes (July 2026, via news feed) — Goldman Neutral $152; J.P. Morgan Overweight $160; Truist Buy $160; Citigroup Buy $138; BofA downgrade to Neutral $125 (6/17/2026, “rising pressure across the Health portfolio”); TD Cowen Hold $115. Cited as market-consensus context, not as valuation authority.
• News feed (AZI) — DHL UK defense-logistics alliance (2026-07-17); Rune Technologies military-logistics collaboration (2026-07-09); defense-sector moves on Middle-East de-escalation (June 2026).

Method & caveats

Every non-obvious fact is dated and, where non-obvious, cited. Facts, interpretations, assumptions and open questions are labeled throughout. Management commentary (guidance, Health-volume and margin framing, AI-as-accelerant) is treated as hypothesis and cross-checked against filings, segment economics, backlog trends, and third-party data. Third-party aggregated figures (ROIC.ai, AZI, FactorsToday) are reconciled to SEC filings, which govern where they disagree. No price target and no buy/sell appears anywhere outside the clearly-labeled Claude’s Take block.